McNeil Nicotrol "labeling" comparative claims targeted in warning letter.
This article was originally published in The Tan Sheet
NICOTROL "ALL PATCHES ARE EQUALLY EFFECTIVE" CLAIM "MISLEADING" without supporting comparative trials, FDA tells McNeil Consumer Products in a Dec. 11 warning letter. FDA notified McNeil that two trade promotions containing several statements comparing the Nicotrol smoking cessation patch to SmithKline Beecham's Nicoderm CQ are deceiving and "cause `Nicotrol' to be misbranded." The brochures have since been recalled, McNeil reports.
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC